The role of inflammation in the pathogenesis of late diabetic complications;Rola zapalenia w patogenezie przewlekłych powikłań cukrzycy

Diabetologia Polska

Volumn 11, Issue 4, 2004, Pages 264-267

  Zozulińska, Dorota ^a   Wierusz Wysocka, Bogna ^a  

^a Oddzial Diabetologii i Chorób Wewnȩtrznych Szp im Fr Raszei ^*  (Poland)

Author keywords

Evidence based medicine; Inflammation; Late diabetic complications

Indexed keywords

ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; CATHEPSIN G; FIBRINOGEN; GLUCOSE TRANSPORTER 4; HEMOGLOBIN A1C; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; URIDINE DIPHOSPHATE N ACETYLGLUCOSAMINE;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; EVIDENCE BASED MEDICINE; HUMAN; HYPERGLYCEMIA; INFLAMMATION; LEUKOCYTE COUNT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR;

EID: 20144363081     PISSN: 12334723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. Sheetz M.J., King G.L. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA, 2002, 288, 2579-2588.
2. Nishikawa T., Edelstein D., Du Liang X. i wsp. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 2000, 404, 787-790.
3. Brownlee M. Glycation and diabetic complication. Diabetes Care, 1994, 43, 836-841.
4. Haller H. Endothelial function. General consideration. Drugs 1997, 53 (Suppl.1), 1-10.
5. Giugliano D., Ceriello A. Oxidative stress and diabetic vascular complications. Diabetes Care, 1996, 19, 257-267.
6. Vlassara H. Recent progress in advenced glycation and products and diabeic complications. Diabetes 1997, 46 (Suppl 2), S19-S25.
7. Marshall S., Rumberger J.M. The hexosamine signaling pathway: role in glucose sensing and integration of cellular metabolism. The Diabetes Annual /13. Wyd. M. Walker, P. Butler, R.A. Rizza. Elsevier Science B.V. 2000: 97-112
8. Koya D., King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes, 1998, 47, 859-866.
9. Tomlinson D.R. Mitogen-activated protein kinases as glucose tranducers for diabetic complications. Diabetologia, 1999, 42, 1271-1281.
10. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 1993, 16, 434-444.
11. Resnick H.E., Howard B.V. Diabetes and Cardiovascular Disease. Annu. Rev. Med., 2000, 53, 245-267.
12. UKPDS Group. UK Prospective Diabetes Study 17: a nine-year update of randomized, controlled trial on the effect of improved metabolic control on complications on non-insulin-dependent diabetes mellitus. Ann. Intern. Medicine, 1996, 124, 136-145.
13. Weis U., Turner B., Gibney J. i wsp. Long-term predictors of coronary artery disease in type 1 diabetes. Q J Med., 2001, 94, 623-630.
14. Danesh J., Whincup P, Walker M. i wsp. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ, 2000, 321, 199-204.
15. Volpato S., Guralnik J.M., Ferrucci L. i wsp. Cardiovascular disease, Interleukin-6 and risk of mortality in older women; The Women's Health and Aging Study. Circulation, 2001, 103, 947-953.
16. Do Lee C., Folsom A.R., Nieto F.J., Chambless L.E., Shahar E., Wolfe D.A. White blood cell count and incidence of coronary heart disease and ischaemic stroke and mortality from cardiovascular disease in African-American and White men and women: Atherosclerosis Risk in Communities Study. Am. J. Epidemiol., 2001, 154, 758-764.
17. Malik I., Danesh J., Whincup P. i wsp. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet, 2001, 358, 971-975.
18. Danesh J., Collins R., Appleby P., Peto R. Association of Fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta-analyses of Prospective Studies. JAMA, 1998, 279, 1477-1482.
19. Jager A., van Hinsbergh V.W., Kostense P.J. i wsp. Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 3071-3078.
20. Matsumoto K., Sera Y., Abe Y., Ueki Y., Tominaga T., Miyake S. Inflammation and insulin resistance are independently related to all-cause of death and cardiovascular events in Japanese patients with type 2 diabetes mellitus. Atherosclerosis, 2003, 169, 317-321.
21. Schulze M.B. i wsp. C-reactive protein is associated with an increased risk of CVD in type 2 diabetic men. Diabetes Care, 2004, 27, 889-894.
22. Saito I., Folsom A.R., Brancati F.L., Duncan B.B., Chambless L.E., McGovern P.G. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Ann. Int. Med., 2000, 133, 81-91.
23. Kilpatrick E.S., Keevil B.G., Jagger C., Spooner R.J., Small M. Determinants of raised C-reactive protein concentration in type 1 diabetes. Q J Med., 2000, 93, 231-236.
24. Nelson J.J., Liao D., Sharrett A.R. i wsp. Serum albumin level as a predictor of incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Am. J. Epidemiol., 2000, 151, 468-477.
25. Adams D.H., Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet, 1994, 343, 831-836.
26. Morigi M., Angioletti S., Imberti B. i wsp. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycaemia in a NF-kB-dependent fashion. J. Clin. Invest., 1998, 101, 1905-1915.
27. Cohen R.A. Dysfunction of vascular endothelium in diabetes mellitus. Circulation, 1993, 87, V67-76.
28. Schmid-Schönbein G.W. The damaging potential of leukocyte activation in the microcirculation. Angiology, 1993, 44, 45-56.
29. Tsujikawa A., Kiryu J., Nonaka A. i wsp. Leukocyte-endothelial cell interactions in diabetic retina after transient retinal ischaemia. Am. J. Physiol. Regulatory Integrative Comp. Physiol., 2000, 279, R980-989.
30. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews, 2004, 25, 581-611.
31. Tilton R.G. Diabetic vascular dysfunction: links to glucose-induced reductive stress and VEGF. Microsc. Res. Tech., 2002, 57, 390-407.
32. Sinclair A.J. Free radical mechanisms and vascular complications of diabetes mellitus. Diabetic Rev., 1993, 2, 7-10.
33. Zozulińska D., Derc K., Majchrzak A., Szczepanik A., Wierusz-Wysocka B. Ocena stȩżenia fibronektyny w osoczu u chorych z typem 1 cukrzycy. Pol. Arch. Med. Wewn., 1999, 3 (9), 773-777.
34. Dzau V.J., Gonzalez D., Kaempfer C., Dubin D., Wintroub B.U. Human neutrophils relase serine proteases capable of activating prorenin. Circulation Res., 1987, 60, 595-605.
35. Fernandez N., Jancar S., Sanchez Crespo M. Blood and endothelium in immune complex-mediated tissue injury. TRENDS in Pharmacol. Sciences, 2004, 25, 512-517.
36. Doganay S., Evereklioglu C., Er H., Türkoz Y., Sevine A., Mehmet N., Savli H. Comparison of serum NO, TNF-α, IL-1β, SIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye, 2002, 16, 163-170.
37. Schram M.T., Chatuverdi N., Schalkwijk C., Giorgino F., Ebeling P., Fuller J.H., Stehouwer C.D. The EURODIAB Prospective Study Group. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in Type 1 diabetes. Diabetes Care, 2003, 26, 2165-2173.
38. Chatuverdi N., Fuller J.H., Pokras F., Rottiers R., Papazoglou N., Aiello L.P. Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition. Diabet. Med., 2001, 18, 288-294.
39. Zozulińska D., Sobieska M., Wiktorowicz K., Majchrzak A., Wierusz-Wysocka B. C-reactive protein is increased in Type I diabetic patients and correlates with markers of endothelial dysfunction. Diabetologia, 2001, 44 (suppl 1), A315.
40. Tong P.C., Lee K.F., Yee W. i wsp. White blood cell count is associated with macro- and microvascular complications in Chinese patients with Type 2 diabetes. Diabetes Care 2004, 27, 216-222.
41. Bruno G., Merletti F., Biggeri A. i wsp. Progression to overt nephropathy in Type 2 diabetes. The Casale Monferrato Study. Diabetes Care 2003, 26, 2150-2155.